{"disease":{"id":"pd-1-ctla-4","name":"pd 1 ctla 4"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT06542549","title":"Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT07131501","title":"A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07128251","title":"A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":47,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT04634058","title":"PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT07004335","title":"Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT04842812","title":"Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT06809530","title":"Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":34,"lead_sponsor_name":"Guangzhou Medical University","has_results":false},{"nct_id":"NCT07447570","title":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":27,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06714084","title":"CNCMT：a Multi-center, Prospective, Single-arm Study","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":20,"lead_sponsor_name":"Hubei Cancer Hospital","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}